Table 7

Exclusion criteria based on ASPECTS or infarct volume in RCTs of MT+BMM versus MT

TrialExclusion criteriaMedian (IQR) ASPECTS or infarct volume (mL) of enrolled patients
MR CLEANNoneMT+BMM: ASPECTS 9 (7–10)
BMM: ASPECTS 9 (8–10)
Extend IAInfarct core ≥70 mLMT+BMM: 12 mL (4–32)
BMM: 18 mL (4–29)
ESCAPEASPECTS ≤5MT+BMM: ASPECTS 9 (8–10)
BMM: ASPECTS 9 (8–10)
SWIFT PRIMEASPECTS ≤5MT+BMM: ASPECTS 9 (7–10)
BMM: ASPECTS 9 (8–10)
REVASCATASPECTS ≤6 (CT)
ASPECTS ≤5 (MRI)
MT+BMM: ASPECTS 7 (6–9)
BMM: ASPECTS 8 (6–9)
THRACENoneDWI lesion volume: 17 mL (9.2–51.8)*
PISTEHypodensity >1/3 of the MCA territoryMT+BMM: ASPECTS 9 (4–10)
BMM: ASPECTS 9 (2–10)
THERAPYHypodensity >1/3 of the MCA territoryMT+BMM: ASPECTS 7.5 (6–9)
BMM: ASPECTS 8 (7–9)
EASINoneMT+BMM: ASPECTS 8 (7–9)
BMM: ASPECTS 9 (8–9)
DAWNInfarct core ≥51 mLMT+BMM: 7.6 mL (2.0–18.0)
BMM: 8.9 mL (3.0–18.1)
DEFUSE-3Infarct core ≥70 mLMT+BMM: 9.4 mL (2.3–25.6)
ASPECTS 8 (7–9)†
BMM: 10.1 mL (2.1–24.3)
ASPECTS 8 (7–9)†
  • *Patients in whom the qualifying imaging study was MRI.

  • †Patients in whom the qualifying imaging study was CT.

  • ASPECTS, Alberta Stroke Program Early CT Score; BMM, best medical management; MCA, middle cerebral artery; MT, mechanical

  • thrombectomy; RCT, randomized controlled trial